ESR1 and non-small cell lung carcinoma: In addition, clinical trials are also evaluating this class of agent in a number of solid cancer settings such as in combination with pembrolizumab in non-small cell lung cancer (NSCLC) (NCT04274907) and with palbociclib (Pfizer, NY, USA) and letrozole (Novartis, Cambridge, MA, USA) in estrogen receptor and Bcl-2 positive breast cancers (NCT03900884), Given the success of venetoclax others are not surprisingly actively pursuing this area.